Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Stopped Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible

Conditions

• Human Papillomavirus Infections

Interventions

• BIOLOGICAL: Ad26.HPV16
• BIOLOGICAL: Ad26.HPV18
• BIOLOGICAL: MVA.HPV16/18
• BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.

Collaborators

• [object Object]